Health & Fitness
Health and Fitness
Health and Fitness
Thu, October 13, 2011
AMRI Appoints New President, India Operations and New Director of Project Management a" Pharmaceutical Services
ALBANY, N.Y.--([ BUSINESS WIRE ])--AMRI (NASDAQ: AMRI) announced today that Mr. Subramanyam Maddala has joined the company as President, India Operations. Mr. Maddala assumes leadership for AMRIa™s Indian API manufacturing operations as well as responsibility for AMRI facility operations in Hyderabad and Aurangabad, India.
"We are pleased to welcome Mr. Maddala to the AMRI leadership team and believe he is the right person to take AMRIa™s chemical manufacturing business in India to the next level, including the capability to eventually manufacture multiple products in India to U.S. FDA standards."
Reporting to Dr. Steven Hagen, vice president of pharmaceutical development and manufacturing at AMRI, Mr. Maddala brings more than 20 years of operations, business development, and senior leadership experience in the manufacturing of APIs and intermediates, custom synthesis, and formulations in branded and generics markets. Most recently, he served as vice president, Contract Research and Manufacturing Services (CRAMS) and New Generics for Shasun Pharmaceuticals Limited, and was responsible for Shasuna™s contract research and manufacturing business, including all vertical CRAMs businesses and new API generic efforts. Prior to that, Mr. Maddala held several roles of increasing responsibility at such firms as Piramal India Limited, Glenmark Pharmaceuticals, Medicorp/Matrix Labs, Torrent Pharmaceuticals, SOL and Lupin Laboratories.
Mr. Maddala earned a Master of Science degree in Applied Chemistry from the University of Baroda, India and a Bachelor of Science degree in Chemistry from Osmania University in Hyderabad, India.
AMRI is also pleased to announce that Dr. Rajesh Shenoy, managing director, AMRI India will be relocating back to the United States to assume the position of director, project management-pharmaceutical services, continuing to report to Dr. Hagen. Dr. Shenoy will have full leadership responsibilities for AMRIa™s global project management activities throughout the pharmaceutical services sector, including small scale, large scale, GMP activities, formulations development and manufacturing, and sterile fill and finish. Dr. Shenoy joined AMRI in 1998. He earned a Ph.D. in organic chemistry at the University of Akron and conducted postdoctoral research at Kent State University. Prior to his assignment in India, Dr. Shenoy held positions of increasing responsibility in AMRIa™s discovery and development services operations.
aWe are pleased to welcome Mr. Maddala to the AMRI leadership team and believe he is the right person to take AMRIa™s chemical manufacturing business in India to the next level, including the capability to eventually manufacture multiple products in India to U.S. FDA standards.a Dr. Hagen continued, aDr. Shenoya™s return to the United States caps a six-year assignment in which he established, built, and oversaw AMRIa™s Hyderabad laboratory operations, eventually assuming leadership for all of our country operations in India, including our manufacturing activities in Aurangabad. We appreciate his continued contributions to AMRI and wish them both great successes in their new roles.a
About AMRI
Founded in 1991, Albany Molecular Research, Inc. (AMRI) provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services, technologies and cost models.
